-Advertisement-
-Advertisement-
Gastroenterology
Dapagliflozin shows positive impact on type 2 diabetes and non-alcoholic fatty liver disease
Dapagliflozin demonstrates significant benefits in improving hepatic function and glucose control in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), according to a meta-analysis. The study, which included 4 randomized controlled trials, found that dapagliflozin treatment led to a notable reduction in key markers such as alanine...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved